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ABSTRACT
Background. Both dialysis dose and residual kidney function
(RKF) contribute to solute clearance and are associated with
outcomes in hemodialysis patients. We hypothesized that the
association between dialysis dose and mortality is attenuated
with greater RKF.
Methods. Among 32 251 incident hemodialysis patients in a
large US dialysis organization (2007–11), we examined the
interaction between single-pool Kt/V (spKt/V) and renal urea
clearance (rCLurea) levels in survival analyses using multivari-
able Cox proportional hazards regression model.
Results. The median rCLurea and mean baseline spKt/V were
3.06 [interquartile range (IQR) 1.74–4.85] mL/min/1.73 m2
and 1.326 0.28, respectively. A total of 7444 (23%) patients
died during the median follow-up of 1.2 years (IQR 0.5–
2.2 years) with an incidence of 15.4 deaths per 100 patient-
years. The Cox model with adjustment for case-mix and
laboratory variables showed that rCLurea modiﬁed the associ-
ation between spKt/V and mortality (Pinteraction ¼ 0.03);
lower spKt/V was associated with higher mortality among pa-
tients with low rCLurea (i.e.<3 mL/min/1.73 m
2) but not
among those with higher rCLurea. The adjusted mortality haz-
ard ratios (aHRs) and 95% conﬁdence intervals of the low
(<1.2) versus high (1.2) spKt/V were 1.40 (1.12–1.74), 1.21
(1.10–1.33), 1.06 (0.98–1.14), and 1.00 (0.93–1.08) for pa-
tients with rCLurea of 0.0, 1.0, 3.0 and 6.0 mL/min/1.73 m
2,
respectively.
Conclusions. Incident hemodialysis patients with substantial
RKF do not exhibit the expected better survival at higher hemo-
dialysis doses. RKF levels should be taken into account when
deciding on the dose of dialysis treatment among incident
hemodialysis patients.
Keywords: dialysis adequacy, dialysis dose, hemodialysis, re-
sidual kidney function, single-pool Kt/V
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INTRODUCTION
Single-pool Kt/Vurea (spKt/V, the clearance of urea multiplied
by dialysis duration and normalized for urea distribution vol-
ume) or the urea reduction ratio (URR) is widely used for evalu-
ating dialysis adequacy among patients with end-stage renal
disease (ESRD) receiving maintenance hemodialysis. Dialysis
dose as expressed in Kt/Vurea or URR has been suggested as an
important predictor of morbidity and mortality in hemodialysis
patients [1–6]. Currently spKt/V is the most frequently applied
measure of delivered dialysis dose, where the recommended
minimum level is set to 1.2 of spKt/V (equivalent to a URR of
65%) for thrice-weekly hemodialysis patients with little or no
residual kidney function (RKF), according to the National
Kidney Foundation–Kidney Disease Outcomes Quality
Initiative (NKF-KDOQI) clinical practice guidelines [7].
RKF in ESRD patients may alter the dialysis dose–survival as-
sociation, and the NKF-KDOQI guidelines in fact suggest that
dialysis dose may be reduced for patients with substantial RKF
provided that renal urea clearance is periodically measured [7].
Although many studies of peritoneal dialysis patients have shown
that the association with better survival is found for greater RKF
but not for higher delivered Kt/V [8–10], evidence for the optimal
dialysis dose, either expressed in spKt/V or URR, is still scarce
among hemodialysis patients with RKF. This issue is increasing
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its importance given that approximately 40% of ESRD patients
have an estimated glomerular filtration rate10 mL/min/
1.73 m2 at dialysis initiation [11] and given that the rates of RKF
decline in hemodialysis patients may be similar to peritoneal dia-
lysis patients under the current standard treatment with biocom-
patible membranes and bicarbonate buffer [12–14].
Although spKt/V remains a useful and common metric of
dialysis adequacy [15] as employed in the ESRD Quality
Incentive Program in the USA, the 2015 update in the KDOQI
guidelines for hemodialysis adequacy did not make specific rec-
ommendations or suggestions on how to reduce the hemodialy-
sis dose according to RKF levels because of lack of evidence [7].
Therefore we investigated the influence of RKF on the associ-
ation between dialysis dose and mortality in a cohort of incident
hemodialysis patients from a large dialysis organization in the
USA. We hypothesized that in patients starting hemodialysis
therapy with significant RKF, there is little to no association be-
tween dialysis dose and survival and that these patients would
require lower initial dialysis doses than anuric patients.
MATERIALS AND METHODS
Patients
We retrospectively extracted, refined and examined data
from all incident hemodialysis patients who initiated treatment
between 2007 and 2011 in facilities operated by a large dialysis
organization in the USA. Patients were considered to be on
maintenance hemodialysis if they were treated for at least 60
consecutive days and were followed through 31 December
2011. Among 142 419 incident ESRD patients who were treated
only by in-center thrice-weekly hemodialysis during the follow-
up, we excluded 33 849 patients who died in the first 90 days of
dialysis, 9958 who had missing data on baseline (i.e. the first
quarter or 91 days of dialysis) variables of body mass index
(BMI), hemoglobin, albumin, creatinine, calcium, phosphorus,
parathyroid hormone (PTH), iron saturation, ferritin and car-
bon dioxide, 2470 who had missing data on baseline spKt/V,
and 63 891 who had missing baseline data on URR or residual
renal urea clearance (rCLurea) (Supplementary data, Figure S1).
Our final study population consisted of 32 251 incident hemo-
dialysis patients. The parent study was approved by the
University of California Irvine Medical Center and University
of Washington. Given the large sample size, anonymity of the
patients studied and nonintrusive nature of the research, the re-
quirement for written consent was waived.
Demographic, clinical and laboratory measures
Information on all-cause death, race/ethnicity, primary in-
surance, vascular access type, comorbidities and laboratory
variables were obtained from the electronic database of the dia-
lysis provider. To minimize measurement variability, averaged
values of laboratory variables during the first patient-quarter
(or the first 91 days of dialysis) within each patient served as
baseline data and were used in all models.
Blood samples were drawn using uniform techniques in all
dialysis clinics and were transported to the central laboratory in
Deland, Florida, USA, typically within 24 h. All laboratory
values were measured by automated and standardized methods.
Most blood laboratory values were measured monthly, includ-
ing serum urea nitrogen, creatinine, albumin, calcium, phos-
phorus and bicarbonate. Serum ferritin and intact PTH were
measured at least quarterly. Hemoglobin was measured at least
monthly in all patients and weekly to biweekly in most patients.
Most blood samples were collected predialysis with the excep-
tion of the postdialysis urea, which was obtained to calculate
urea kinetics.
Residual rCLurea was used as the index of RKF in all analyses.
The average serum urea concentrations during urine collection
were assumed to be 90% of the predialysis concentrations ac-
cording to the Daugirdas approach [16] and thus rCLurea was
calculated as follows:
rCLurea mL=minð Þ
¼ urinary urea nitrogen mg=dLð Þ  urinary volume ðmLÞ
collected time minð Þ  ½0:9 serum urea nitrogen mg=dLð Þ ;
where serum urea nitrogen was obtained on the closest day
within628 days of urine collection. Urine collected time was
reported as 1440 min in 98% of measurements, ranging from
720 to 2880 min. rCLurea was then adjusted for body surface
area and expressed as mL/min/1.73 m2 [17, 18]. Normalized
protein catabolic rate (nPCR) was calculated with accounting
for rCLurea [19].
SpKt/V or URR was used as the index of hemodialysis ad-
equacy. We used the second-generation logarithmic estimates
of spKt/V [20, 21]:
SpKt=V ¼ ln R 0:0174
PIDI
 t
60
 
þ 4 3:5 Rð Þ  0:55 UF
V
;
where R is the ratio of the pre- and posthemodialysis concentra-
tions of serum urea, PIDI is the length of the preceding interdia-
lysis interval (days), t is the duration of hemodialysis treatment
time (minutes), UF is the amount of ultrafiltration (L) during
the given hemodialysis session and V is the estimated urea dis-
tribution volume.
Statistical analyses
Patients were categorized into two groups according to base-
line rCLurea strata (<3.0 or 3.0mL/min/1.73 m2). The cutoff
value of 3.0 mL/min/1.73 m2 was selected based on the defin-
ition of ‘substantial RKF’ in previous studies and guidelines [22,
23]. Differences in baseline characteristics between included
versus excluded patients and between two rCLurea strata were
compared by standardized differences due to the large sample
size of this study [24, 25]. Since the missing frequency was high
in rCLurea, we used inverse probability weighting to mitigate se-
lection bias in our observational study [26]. In short, the prob-
ability of having data on rCLurea were calculated among patients
with data on all covariates except for rCLurea and nPCR that
accounted for rCLurea by a logistic regression model and patients
were weighted based on their inverse probabilities. SpKt/V and
URR were treated as categorical variables in the primary analyses
and their association with all-cause mortality was examined by
inverse probability-weighted Cox proportional hazards models.
1824 M. Wang et al.
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As the sensitivity analyses, we also examined potential nonlinear
relationships by using restricted cubic spline functions with four
knots at the 5th, 35th, 65th and 95th percentiles of each index
and the reference spKt/V and URR were 1.4 and 0.65,
respectively.
For each analysis we employed hierarchical adjustment with
four models as follows:
1. Model 1 included baseline spKt/V or URR.
2. Model 2 included the above variables plus case-mix vari-
ables including age, sex, race/ethnicity, primary insurance,
central venous catheter use, hypertension, diabetes, history
of cardiovascular disease (i.e. congestive heart failure, ath-
erosclerotic heart disease, cerebrovascular disease or other
cardiovascular disease) and rCLurea.
3. Model 3 included the above variables plus BMI, nPCR,
hemoglobin, serum albumin, creatinine, calcium, iron sat-
uration, total bicarbonate and ferritin.
4. Model 4 included the above variables plus serum phos-
phorus and natural log-transformed intact PTH.
We defined Model 3 as the primary model because serum
phosphorus and intact PTH may be located in the pathways
between spKt/V and mortality (i.e. intermediates) [27–30].
We also did not include volume parameters such as interdia-
lytic weight gain and ultrafiltration rate in the adjustment
models since these factors are considered intermediates.
Effect modification of the association between spKt/V or URR
and mortality were evaluated by adding a product term be-
tween continuous spKt/V and each of a priori–defined vari-
ables, including baseline age (65 or <65 years), gender, race
(white or nonwhite), diabetes, presence of congestive heart
failure, serum albumin (3.6 or <3.6 g/dL) and BMI (30 or
<30) into Model 3 and by conducting the subgroup analyses
in each rCLurea category. Additionally we evaluated the
change in the mortality risk associated with low spKt/V (<1.2
versus1.2) over rCLurea levels by including restricted cubic
spline functions for rCLurea and their interactions with low
spKt/V in Model 3.
The frequency of missing data was 6% for nPCR, and mul-
tiple imputation methods with five data sets were used in all re-
gression analyses. Analyses were conducted using STATA MP
version 13.1 (StataCorp, College Station, TX, USA).
RESULTS
Baseline characteristics
The cohort included 32 251 incident hemodialysis patients
in whom the mean6 SD age was 626 15 years, of which 63%
were male, 54% were Caucasian, 28% were African American
and 59% were diabetic. Mean baseline spKt/V and URR were
1.32 6 0.28 and 0.66 6 0.07, respectively. The median rCLurea
was 3.06 [interquartile range (IQR) 1.74–4.85] mL/min/1.73 m2
and the prevalence of patients with low (<3.0 mL/min/1.73 m2)
and high (3.0 mL/min/1.73 m2) rCLurea levels were 49 and
51%, respectively. Patients with greater rCLurea tended to be
male; had lower levels of spKt/V, URR, serum creatinine and
phosphorus and had higher levels of nPCR and hemoglobin
(Table 1). A total of 7444 (23%) patients died during the me-
dian follow-up of 1.2 years (IQR 0.5–2.2) with an incidence of
15.4 deaths per 100 patient-years. Compared with 76 319
excluded patients, 32 251 included patients were more likely to
be male, Caucasian and had lower spKt/V and URR levels
(standardized difference >0.2; Supplementary data, Table S1).
After weighting patients by inverse probability of having data
on rCLurea and nPCR, those variables were well balanced be-
tween those with versus without rCLurea (Supplementary data,
Table S2).
Association of spKt/V and all-cause mortality according
to rCLurea strata
There was a trend toward higher mortality risk across higher
spKt/V levels in the unadjusted model (i.e. Model 1) in high
rCLurea category (Ptrend ¼ 0.8 and <0.001 for the low and high
rCLurea, respectively; Figure 1). However, the association be-
tween spKt/V and all-cause mortality was significantly modified
by rCLurea levels after adjustment for case-mix variables and la-
boratory variables (Pinteraction ¼ 0.01 and 0.03 for Models 2 and
3, respectively). In Model 3 there was a significant trend toward
higher mortality across lower spKt/V categories among patients
with low rCLurea (Ptrend < 0.001) but not among those with
high rCLurea (Ptrend¼ 0.4), and the adjusted hazard ratio (aHR)
for mortality of the lowest (<1.0) versus the middle (1.2–1.4)
spKt/V quintile group was 1.17 [95% confidence interval (CI)
1.00–1.38] and 1.08 (95% CI 0.95–1.23) for patients with low
versus high rCLurea, respectively.
We then evaluated the mortality risk associated with low
spKt/V (<1.2 versus 1.2) over rCLurea levels using spline
functions for rCLurea and their interactions with low spKt/V
(Figure 2). The risk associated with low spKt/V was higher with
lower rCLurea, showing an increased mortality risk in the range
of rCLurea <3.0 mL/min/1.73 m
2 with aHRs of 1.21 (95% CI
1.10–1.33) and 1.11 (95% CI 1.04–1.20) at rCLurea of 1.0 and 2.0
mL/min/1.73 m2, respectively. Meanwhile, low spKt/V was not
associated with mortality in greater rCLurea levels with aHRs of
1.06 (95% CI 0.98–1.14) and 1.00 (95% CI 0.93–1.08) at rCLurea
of 3.0 and 6.0 mL/min/1.73 m2, respectively. Consistent associa-
tions were observed in Models 2, 3 and 4 (Supplementary date,
Figure S2).
In Model 4, which included serum phosphorus and natural
intact PTH on top of the variables in Model 3, the modification
of the association between spKt/V and mortality by rCLurea was
attenuated (Pinteraction¼ 0.06), which may be due to overadjust-
ment because phosphorus and intact PTHmay be at least partly
intermediates between spKt/V and mortality.
Subgroup analysis of the association between spKt/V
and all-cause mortality according to rCLurea strata
Subgroup analysis of the associations of low (<1.2) and high
(1.4) spKt/V with mortality were examined in Model 3 (refer-
ence 1.2–<1.4). Consistent with the findings above, a signifi-
cant trend was observed between lower spKt/V categories and
higher mortality among patients with low rCLurea
(Ptrend < 0.001) but not among those with high rCLurea
(Ptrend ¼ 0.4; Figure 3). Among patients with low rCLurea, the
Residual kidney function, hemodialysis adequacy and mortality 1825
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association between spKt/V and mortality was not modified
by baseline age, gender, race, diabetes, presence of congestive
heart failure, serum albumin and BMI (Pinteraction > 0.05
for all; Figure 3A). However, among patients with high
rCLurea levels, the association between spKt/V and mortality
was modified by gender (Pinteraction¼ 0.01) where low spKt/V
was associated with higher mortality risk in female
(Ptrend ¼ 0.01) but not in male patients (Ptrend ¼ 0.4;
Figure 3B).
Sensitivity analysis using URR
The associations of URR with mortality in Models 1–4 were
consistent with those of spKt/V. The Model 3 aHRs of the low-
est (<0.60) and highest (0.75) URR, when compared with the
Table 1. Baseline characteristics of 32 251 incident hemodialysis patients stratiﬁed by baseline residual rCLurea
Characteristics Total rCLurea (mL/min/1.73 m
2) Standardized
difference
<3.0 3.0
(n ¼ 32 251) (n ¼ 15 786) (n ¼ 16 465)
CLurea (mL/min/1.73 m
2), median (IQR) 3.06 (1.74–4.85) 1.72 (1.05–2.35) 4.80 (3.80–6.40) 2.03
Urine volume (mL/24 h), median (IQR) 800 (490–1300) 500 (300–700) 1200 (850–1675) 1.74
Age (years), mean6 SD 61.96 14.8 62.36 15.3 61.56 14.3 0.05
Male, % 63 57 69 0.25
Race, %
White 54 51 58 0.14
Black 28 31 24 0.16
Hispanic 11 11 11 0.02
Asian and others 7 7 8 0.04
Primary insurance, %
Medicare 51 53 50 0.06
Medicaid 6 7 6 0.04
Others 42 40 44 0.08
Vascular access, %
Central venous catheter 74 77 70 0.16
AV ﬁstula/graft 22 18 26 0.18
Unknown 4 4 4 0.00
Comorbidities, %
Diabetes 59 58 61 0.07
Hypertension 51 53 49 0.08
Congestive heart failure 39 40 38 0.04
Atherosclerotic heart disease 14 14 14 0.01
Cerebrovascular 2 2 1 0.02
Other cardiovascular disease 15 16 15 0.01
Dyslipidemia 26 26 27 0.03
Infection 81 82 81 0.01
Malignancy 3 3 2 0.01
spKt/V, mean6 SD 1.326 0.28 1.376 0.28 1.286 0.27 0.31
Urea reduction ratio (%), mean6 SD 666 7 676 7 656 7 0.29
Body mass index (kg/m2), median (IQR) 27.4 (23.6–32.6) 27.3 (23.5–32.7) 27.5 (23.8–32.6) 0.03
Weekday IDWG (kg), median (IQR) 1.7 (1.2–2.4) 1.8 (1.2–2.4) 1.7 (1.1–2.4) 0.11
Weekend IDWG (kg), median (IQR) 2.4 (1.6–3.3) 2.5 (1.7–3.4) 2.2 (1.5–3.1) 0.20
Ultraﬁltration rate (L/h), mean6 SD 0.596 0.24 0.616 0.23 0.576 0.25 0.13
nPCR (g/kg/day), mean6 SD 0.986 0.28 0.906 0.25 1.066 0.29 0.58
ESRD reason, %
Diabetes 47 45 49 0.10
Hypertension 28 31 26 0.10
Glomerulonephritis 10 10 10 0.00
Cystic kidney disease 2 2 2 0.05
Other 13 13 12 0.03
Laboratory variables
Hemoglobin (g/dL), mean6 SD 11.36 1.1 11.16 1.1 11.46 1.1 0.20
Albumin (g/dL), mean6 SD 3.576 0.46 3.546 0.46 3.606 0.45 0.14
Creatinine (mg/dL), mean6 SD 5.96 2.3 6.56 2.6 5.36 1.9 0.55
Corrected calcium (mg/dL), mean6 SD 9.16 0.5 9.16 0.6 9.16 0.5 0.00
Phosphorus (mg/dL), mean6 SD 5.06 1.1 5.26 1.2 4.86 1.0 0.28
Intact PTH (pg/mL), median (IQR) 315 (203–478) 332 (213–514) 300 (194–446) 0.17
Iron saturation (%), mean6 SD 236 8 236 8 236 8 0.01
Ferritin (ng/mL), median (IQR) 268 (156–448) 281 (165–472) 255 (148–427) 0.13
Bicarbonate (mEq/L), mean6 SD 23.46 2.6 23.66 2.6 23.26 2.6 0.15
Conversion factors for units: albumin and hemoglobin in g/dL to g/L, 10; creatinine in mg/dL to mmol/L, 88.4; calcium in mg/dL to mmol/L, 0.2495; phosphorus in mg/dL to mmol/L,
0.3229. No conversion is necessary for ferritin in ng/mL and mg/L. IDWG, interdialytic weight gain.
1826 M. Wang et al.
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middle URR (0.65–0.70), were 1.20 (95% CI 1.07–1.35) and
0.86 (95% CI 0.77–0.97), respectively, for patients with low
rCLurea (Ptrend<0.001) and 1.09 (95% CI 0.98–1.22) and 0.95
(95% CI 0.82–1.09), respectively, for patients with high rCLurea
(Ptrend¼0.1; Figure 4). Models using spline functions yielded
consistent results (Supplementary data, Figure S3).
In subgroup analysis using three URR categories (<0.65,
0.65–<0.70 and0.70), the mortality risk of low URR was fur-
ther pronounced among patients with low rCLurea whereas the
association between low URR and higher mortality was attenu-
ated if serum albumin level was low (Pinteraction ¼ 0.03)
(Figure 5A). Similar to the results based on spKt/V, among pa-
tients with high rCLurea, there was a significant trend toward
lower mortality across higher URR categories when patients
were female (Ptrend ¼ 0.002) but not when patients were male
(Ptrend¼ 0.5, Pinteraction¼ 0.01; Figure 5B).
DISCUSSION
In the present study, the association of a higher spKt/V (or
URR) with better survival was observed among patients with
low RKF (rCLurea <3.0 mL/min/1.73 m
2) but was attenuated
among those with substantial RKF (rCLurea3.0 mL/min/
1.73 m2). The 2006 updates on the KDOQI clinical practice
guidelines underscored that the cutoff value of 1.2 for minimum
spKt/V can be applied to patients with little or no RKF since it
was derived from studies excluding patients with RKF or those
assuming no RKF among participants [23, 31, 32]. Our results
were consistent with these previous studies in terms of the
dialysis dose–mortality association among patients with low
rCLurea [28, 33–35]. The 2006 KDOQI guidelines also suggest
that the minimum spKt/V can be reduced for patients with sub-
stantial RKF based on the urea kinetic model indicating that
rCLurea of 2.0 mL/min/1.73 m
2 corresponds to 0.67 weekly
Kt/V [23], but there has been little evidence supporting this kin-
etic model–derived hypothesis. A recent study by Swaminathan
et al. [36] indicated that 4 h of dialysis treatment (versus 3 h)
is associated with a lower mortality risk among incident hemo-
dialysis patients. Because dialysis dose increases with longer
treatment time, these study results may seem to conflict with
ours; however, our study differs by our evaluation of effect
modification by RKF.
Our finding that the association of dialysis dose with mortal-
ity is strongly dependent on RKF levels is consistent with the
Netherlands Cooperative Study on the Adequacy of Dialysis
(NECOSAD)-2 study, where lower dialysis dose was incre-
mentally associated with higher mortality only among an-
uric patients [37]. Both studies included incident hemodialysis
patients, but these discrepant cutoff values in rCLurea
(i.e. 3.0 versus <3.0 mL/min/1.73 m2 in our study and the
presence versus absence of RKF in the NECOSAD-2 study)
may result from the difference in analytical methods; the
NECOSAD-2 study used a time-varying covariate Cox model
FIGURE 1: Association of baseline spKt/V with all-cause mortality in 32 251 incident hemodialysis patients with baseline rCLurea of (A)
<3.0 mL/min/1.73 m2 and (B) 3.0 mL/min/1.73 m2 in four adjusted models.
FIGURE 2: The change in the mortality risk associated with low
spKt/V (<1.2 versus 1.2) over rCLurea levels in 32 251 incident
hemodialysis patients.
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to evaluate short-term associations, while we focused on long-
term associations by using a conventional fixed covariate Cox
model considering the time frame required for dialysis dose to
impact on patient survival.
Given that incident ESRD patients start dialysis at a wide
range of RKF levels and that the benefit of greater RKF is
substantial even at such small differences as observed in this
population, simple dichotomization may not be adequate to
untangle the interactions among RKF, dialysis adequacy and
survival. The large sample size of this study enabled us to dem-
onstrate that the risk associated with low spKt/V (i.e. <1.2 ver-
sus 1.2) was linearly attenuated with greater CLurea. We also
provided specific HRs of low spKt/V for all-cause mortality at
different CLurea levels. These detailed data allow us to assess the
potential risk associated with low dialysis dose based on the in-
dividual RKF level of each patient, which may facilitate tailored
dialysis prescriptions in future clinical practice.
Our results are also supported by a recent observational study
demonstrating that incident hemodialysis patients on incremen-
tal frequency regimens (i.e. starting hemodialysis with a twice-
weekly schedule), which is inherently accompanied by reduced
dialysis dose, experienced a similar mortality as those with con-
ventional thrice-weekly regimens if patients had substantial RKF
[38]. These two studies are complimentary to each other, but the
findings of this study can be applicable to a much wider popula-
tion given that the vast majority of hemodialysis patients in de-
veloped countries routinely receive thrice-weekly treatment.
Patients with greater RKF experienced less weekend inter-
dialytic weight gain in this study. Given that an excess of ultra-
filtration or intradialytic hypotension in relation to interdialytic
weight gain has been associated with higher mortality in both
incident and prevalent hemodialysis patients [39–42], more sta-
ble intradialytic hemodynamics resulting from less ultrafiltra-
tion among patients with greater RKF may partly explain the
attenuation in the association between dialysis adequacy and
mortality. Additionally, such hemodynamic stability may also
preserve more RKF, leading to a positive feedback loop. Other
proposed strategies to preserve RKF include avoidance of
nephrotoxic agents, a low-protein diet on nondialysis days, the
use of ultrapure dialysate and an incremental/infrequent ap-
proach to hemodialysis initiation [43].
Higher dialysis dose was consistently associated with lower
mortality among women, even if they had substantial RKF. As a
urea distribution volume-based scaling of dialysis dose, spKt/V
is often overestimated in women, especially in small-size
women, due to their relatively less water-rich muscle mass and
possibly due to RKF [44–46], whereby women may be under-
dialyzed under standard spKt/V. Indeed, the Hemodialysis
(HEMO) Study suggested that the intensive dialysis dose, com-
pared with the standard dose, reduced mortality and morbidity
in women but not in men [27]. A consistent finding was
observed among patients with substantial RKF in our study.
However, it remains unclear why the interaction between gender
and dialysis dose was not observed among patients with little or
FIGURE 3: Association of baseline URR with all-cause mortality in 32 251 incident hemodialysis patients with baseline rCLurea of (A)
<3.0 mL/min/1.73 m2 and (B) 3.0 mL/min/1.73 m2 in four adjusted models.
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no RKF. These results should be considered suggestive due to
multiple comparisons and need to be verified in future studies.
Among patients with low rCLurea, the association between
low URR and greater mortality was attenuated while the asso-
ciation between high URR and lower mortality was pro-
nounced if the patient had low albumin levels. However, these
findings were not confirmed by using spKt/V as an index of
dialysis dose. Nevertheless, trends of the change in the abso-
lute effect size were similar between URR and spKt/V in either
case. A higher threshold of dialysis dose may be necessary for
patients with higher serum albumin if they have low or little
RKF.
FIGURE 5: Overall and subgroup analysis of association between URR and all-cause mortality in 32 251 incident hemodialysis patients with
baseline rCLurea of (A) <3.0 mL/min/1.73 m
2 and (B) 3.0 mL/min/1.73 m2 in Model 3. Points and bars represent HR estimates and 95% CIs,
respectively. Alb, albumin; BMI, body mass index; CHF, congestive heart failure; DM, diabetes mellitus.
FIGURE 4: Overall and subgroup analysis of association between spKt/V and all-cause mortality in 32 251 incident hemodialysis patients with
baseline rCLurea of (A) <3.0 mL/min/1.73 m
2 and (B) 3.0 mL/min/1.73 m2 in Model 3. Points and bars represent HR estimates and 95% CIs,
respectively. Alb, albumin; BMI, body mass index; CHF, congestive heart failure; DM, diabetes mellitus.
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There have been conflicting data among large clinical trials
evaluating dialysis dose and frequency. For example, while
maintaining lower urea nitrogen concentrations decreased
treatment withdrawals and hospitalizations in the National
Cooperative Dialysis Study [31], higher dialysis dose did not im-
prove patient survival in the HEMO Study [47]. Additionally,
the Frequent Hemodialysis Network reported better survival
with daily six-times-per-week in-center hemodialysis [48] and
higher mortality with nocturnal six-times-per-week home
hemodialysis [29] compared with conventional thrice-weekly
in-center hemodialysis. Although the reasons for those incon-
sistent results remain unclear, it should be noted that clinical
trials generally have limited external validity and inadequate
statistical power to detect heterogeneity in the treatment effect.
The efficacy of higher dialysis adequacy may actually be modi-
fied by several factors, including patient body size, dialysis vin-
tage, treatment time, treatment frequency and RKF [7]. Our
findings support the potential of RKF as a strong and linear ef-
fect modifier, which needs to be examined in further studies.
Although, due to the observational nature of this study, we can-
not prove causality between dialysis dose andmortality, the cur-
rently recommended minimum dialysis dose (i.e. 1.2 in spKt/V)
is also based on observational studies and is applicable only in
patients with rCLurea<2.0 mL/min/1.73 m
2 [7].
Our study should be qualified for several other limitations.
First, there may also be residual confounding or unmeasured
confounders such as inadequate predialysis care. Second,
spKt/V and URRmay have varied over time. We focused on the
long-term association of dialysis dose in the early period of dia-
lysis with long-term mortality in this study, and further studies
are required to examine the relationships among longitudinal
changes in dialysis dose, RKF decline and mortality. Third,
RKF may not be accurate given the use of urea clearance, the
difficulties in punctual and complete collection of urine samples
and the use of factor 0.9 for estimating average predialysis
serum urea. Nevertheless, the population-level associations can
be estimated from an adequate number of subjects if such errors
are not associated with the outcome, and a recent study has
shown that the change in rCLurea used in this study was closely
related to all-cause mortality [22]. Fourth, medications were
not included in the adjustment model. However, in contrast to
the peritoneal dialysis population, even renin–angiotensin sys-
tem inhibitors, the representative renoprotective drug type, do
not have any effect on RKF among hemodialysis patients [49].
In addition, potential selection bias may exist since patients
with limited RKF are less likely to have undergone urine collec-
tions. The employment of inverse probability weighting for
having data on RKF is our best effort to mitigate selection bias
in this study. Nevertheless, our findings may not be extrapo-
lated to those settings with different practice patterns from the
USA, such as dialyzer reuse, inadequate water purification and
schedules other than thrice-weekly treatment.
In conclusion, RKF at dialysis start modified the association
of initial dialysis dose with all-cause mortality among incident
hemodialysis patients. Further research, including clinical trials,
is necessary to test if an incremental hemodialysis approach
with a reduced dialysis dose by either less treatment time or a
less frequent schedule among patients with substantial RKF
during the first several months of dialysis is an economic strat-
egy that enhances patients’ quality of life without compromis-
ing their survival [50, 51].
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